The report provides market intelligence on hepatitis C (HCV) diagnostics and drugs in low- and middle-income countries to help guide elimination of the disease. It also covers preliminary insights into the hepatitis B (HBV) market. We are pleased to release the second...
CHAI is pleased to share news today from MedAccess of measures to increase access to a patient-friendly preventative therapy for tuberculosis (TB). The volume guarantee agreement between MedAccess and Macleods Pharmaceuticals, in partnership with CHAI and...
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI. Please tell us a bit about your background and what brought you to CHAI. I grew up in France and studied veterinary medicine there. I have always been fascinated by...
Hepatitis B (HBV) is an incurable liver infection that can lead to severe health consequences including liver failure and liver cancer. It is a silent killer – most people do not experience any symptoms when they get infected and children in particular are less able...
Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announce pricing agreement with pharmaceutical company Hetero Labs LTD to make available generic version of best-in-class second-line therapy for people living with HIV. July 26, 2021 – Unitaid and CHAI...
